OTIC
NASDAQ:OTIC
Otonomy, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.otonomy.comipo date
Aug 13, 2014
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase II...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus